Developing a transformative pan-cancer drug that unleashes the true potential of I/O

Immunotherapies have turned some once-deadly cancers, like metastatic melanoma, into curable diseases—but for most patients, long-term remission remains out of reach. MomentousTx is developing a drug that targets a fundamental mechanism, discovered at Cambridge University, that appears to be relevant across most cancer types. Current immunotherapies—checkpoint inhibitors and CAR-T cells—are approved for about 20 different cancers, yet true cures are rare. The problem is that tumours often find ways to evade or suppress the immune response, even when these therapies are used. This new drug aims to remove that evasion, unlocking the full potential of existing immunotherapies. If it succeeds, it could extend durable cures to far more patients and many more cancer types than are currently treatable. The impact would be felt directly in oncology clinics: more people surviving cancers that today are managed, not cured. The work is applied drug development, not fundamental science, but it builds directly on a discovery about how cancer cells hide from the immune system.